The Purified Human CD274 (PD-L1) Monoclonal Antibody (29E.2A3) (AGEL1646) is a powerful tool for researchers studying the PD-L1 protein, a key immunomodulatory molecule involved in suppressing the immune response. This monoclonal antibody, produced using innovative purification techniques, exhibits high specificity and sensitivity when detecting human PD-L1, making it a reliable choice for a variety of research applications.PD-L1, also known as programmed death-ligand 1, has garnered significant interest in the field of immuno-oncology for its role in immune evasion and immune tolerance mechanisms exploited by cancer cells. By targeting PD-L1, researchers aim to unravel its intricate involvement in immune checkpoint pathways and explore its potential as a therapeutic target in cancer treatment strategies.
With its ability to selectively bind to PD-L1, the 29E.2A3 monoclonal antibody facilitates precise detection and analysis of PD-L1 expression in diverse experimental settings. Whether investigating PD-L1 levels in tumor cells, evaluating immune checkpoint blockade therapies, or exploring the immune landscape of malignancies, this antibody provides researchers with a valuable tool for advancing their understanding of PD-L1 biology and its implications in cancer immunotherapy.By utilizing the Purified Human CD274 (PD-L1) Monoclonal Antibody (29E.2A3) (AGEL1646), researchers can delve deeper into the complexities of PD-L1-mediated immune regulation and expedite the development of innovative approaches to modulate the immune response for therapeutic benefit in cancer and other immune-related disorders.
Each lot of this antibody is quality control tested by flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 µg per 106 cells in 100 µL volume or 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Keep as concentrated solution. Store at 2~8°C and protected from prolonged exposure to light. Do not freeze. Centrifuge before opening to ensure complete recovery of vial contents. This product is guaranteed up to one year from purchase.
Background:
CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells.